Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultevursen (QR-421a) in Early-Moderate USH2A-Mediated Retinitis Pigmentosa
NCT05176717Phase 3Terminated
- Sponsor
- Laboratoires Théa
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) and Usher syndrome type 2 (USH2) (3 arms), sponsored by Laboratoires Théa. Primary endpoint: Change From Baseline in Mean Sensitivity at 12 months. Started Dec 2021; status: terminated.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2 (USH2)
Beyond the preview
Go deeper on NCT05176717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176717.